IDEXX Laboratories, Inc. IDXX
519.26
5.87
1.14%
as of 25 Sep
- Market cap
- $40.2B
- P/E
- 36.2×
Follow IDXX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| P/E ratio |
+8 more quarters Free account |
50.27 | 51.33 | 41.01 | 36.74 |
| P/S ratio | 12.28 | 12.64 | 10.07 | 9.13 | |
| P/FCF ratio | 59.28 | 56.88 | 42.30 | 33.60 | |
| P/Operating CF | 127.19 | 152.94 | 168.09 | 119.73 | |
| P/B ratio | 32.78 | 33.89 | 28.76 | 25.78 | |
| Price to Tangible BV | 49.55 | 50.31 | 43.06 | 37.67 | |
| EV/Sales | 12.36 | 12.71 | 10.12 | 9.18 | |
| EV/EBITDA | 35.60 | 36.33 | 28.94 | 25.93 | |
| EV/Operating CF | 47.32 | 46.27 | 37.19 | 30.49 | |
| EV/FCF | 59.65 | 57.16 | 42.53 | 33.80 | |
| Quick Ratio | 0.62 | 0.64 | 0.62 | 0.64 | |
| Current Ratio | 1.18 | 1.23 | 1.12 | 1.17 | |
| Net Debt/EBITDA | 0.81 | 0.76 | 0.62 | 0.54 | |
| Debt/Assets | 15.50% | 13.42% | 13.29% | 13.07% | |
| Debt/Equity | 0.34 | 0.28 | 0.29 | 0.28 | |
| Asset Turnover | 1.24 | 1.30 | 1.35 | 1.34 | |
| Operating CF/Net income | 1.47 | 1.43 | 0.96 | 1.03 | |
| Capex/Depreciation | (1.21) | (0.77) | (0.90) | (0.65) | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 5.74% | 6.13% | 5.77% | 5.38% | |
| Selling, General and Administrative Expense of Revenue | 23.99% | 25.28% | 25.80% | 23.68% | |
| Intangible Assets out of Total Assets | 0.16 | 0.16 | 0.15 | 0.15 | |
| Share Based Compensation of Revenue | 1.31% | 1.48% | 1.43% | 1.32% | |
| Graham Net Nets | (0.01) | (0.01) | (0.01) | (0.01) | |
| Graham Number | 74.66 | 76.94 | 77.60 | 81.15 | |
| Earnings Yield | 1.99% | 1.95% | 2.44% | 2.72% | |
| Free Cash Flow Yield | 1.69% | 1.76% | 2.36% | 2.98% | |
| Revenue per Share | 13.80 | 13.56 | 14.32 | 15.41 | |
| Operating CF per Share | 5.02 | 4.42 | 3.34 | 4.40 | |
| Capex per Share | (0.56) | (0.37) | (0.42) | (0.34) | |
| Free Cash Flow per Share | 4.47 | 4.05 | 2.92 | 4.06 | |
| Cash per Share | 2.60 | 2.24 | 2.52 | 2.49 | |
| Shareholders Equity per Share | 19.49 | 19.96 | 19.54 | 20.42 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 19.49 | 19.96 | 19.54 | 20.42 | |
| Free Cash Flow | 357.88 | 326.13 | 232.46 | 320.62 | |
| Working Capital | 225.24 | 265.01 | 154.22 | 221.82 | |
| Capital Expenditures | (44.46) | (29.63) | (33.78) | (26.54) | |
| Net Current Asset Value | (348.47) | (331.55) | (375.32) | (320.27) | |
| EV/EBIT | 39.42 | 40.21 | 32.01 | 28.67 | |
| Capex to Sales | 0.04 | 0.03 | 0.03 | 0.02 | |
| Net Profit Margin | 24.85% | 22.76% | 24.41% | 27.82% | |
| Price to Operating Income | 39.18 | 40.01 | 31.83 | 28.50 | |
| Other line items | |||||
| Average Receivables | 539.07 | 512.98 | 565.50 | 593.82 | |
| Average Payables | 116.43 | 112.31 | 125.04 | 122.84 | |
| Average Inventory | 390.68 | 379.82 | 389.19 | 392.08 | |
| Average Assets | 3,368.74 | 3,322.10 | 3,299.59 | 3,386.56 | |
| Average Common Equity | 1,589.62 | 1,600.35 | 1,502.06 | 1,535.70 |
Columns are period end dates